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INTRODUCTION
Intracystic papillary breast tumors (ICPT) consist of benign papillomas, carcinomas in situ and carcinomas with invasion, and they account for approximately 10% of benign breast tumors and less than 1% of malignant tumors, respectively (1, 2) .
Intracystic papillary carcinoma develops predominantly in elderly women, who often present with a palpable mass and/or bloody nipple discharge. Although this type of carcinoma has a good prognosis, regardless of whether the tumor is diagnosed as in situ or invasive (3) , some cases with metastasis to lymph nodes or to distant organs have been reported (4) (5) (6) .
Cytogenetic studies of breast papillary tumors, which are considered useful for clinical diagnosis and for understanding tumorigenesis, are limited and cytogenetic differences between papillomas and papillary carcinomas are still controversial. Tsuda et al. (7, 8) reported that papillary carcinomas have frequent changes in gene copynumber and loss of heterozygosity (LOH), while papillomas did not show any gene copy-number alteration or LOH at 16q and 1q. Boecker et al. (9) also reported that conventional comparative genomic hybridization (CGH) did not reveal any gene copynumber change in papillomas. On the other hand, Lininger et al. (10) and Cristofano et al. (2) demonstrated that LOH at 16p or 16q was frequent in both papillomas and papillary carcinomas.
Recent technological progress has enabled CGH analysis with higher resolution using high-density array CGH (aCGH) (11) . In breast cancer, aCGH studies have revealed genomic regions where DNA copy number is commonly changed. Novel candidate oncogenes or anti-oncogenes have been found in these regions, and relationships between genomic alteration and the clinical phenotypes and/or prognosis have been suggested (12) (13) (14) (15) . Analysis with high-density single nucleotide polymorphism (SNP) microarrays has the advantage of performing comprehensive genome-wide analyses of genomic alteration. The use of intensity data and genotype data from SNP-specific probes enables not only copy number detection but also copy number neutral LOH detection (16) (17) (18) (19) . Although this analysis requires high quality genomic DNA, such as DNA extracted from peripheral blood or rapidly-frozen samples, some modifications to the protocol and statistical processing have enabled us to use degraded genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) 4 samples (20) (21) (22) (23) . This enables the utilization of a large and growing deposit of archived clinical tissues that are stored as FFPE samples.
In this article, we reveal the profile of genomic alteration in breast ICPT using FFPE samples and show, for the first time, the possibility of using high-density oligonucleotide SNP arrays as the basis of a novel diagnostic method of ICPT.
MATERIALS AND METHODS

Tumor samples and clinical characteristics
Ten FFPE breast ICPTs were obtained from the Department of Pathology, Nagasaki University Hospital. The samples included five benign papillomas (Pap), three papillary carcinomas in situ (PurePC) and two papillary carcinomas with invasion (PCinv).
Pathological diagnosis was independently determined by two pathologists. Categorical diagnosis was determined from imaging studies by radiologists specializing in breast disease in accordance with the Breast Imaging-Reporting and Data System (BI-RADS) of the American College of Radiology and the diagnostic guidelines of the Japanese Association of Breast and Thyroid Sonology (JABTS). Clinicopathological findings of these tumors are provided in Figure 1 , Table 1 and Supplementary Table 1. All experimental procedures for this study were approved by the Committee for Ethical Issues on the Human Genome and Gene Analysis of Nagasaki University and all patients provided informed consent for voluntary participation.
DNA extraction and hybridization to SNP arrays
Using ten to twenty 10 m thick sections cut from FFPE blocks, tumor tissue areas containing more than 90% tumor cells and normal tissue areas not having any cancer cells, which were identified by staining with hematoxylin and eosin, were microdissected. Paraffin removal was performed in 80% xylene and samples were then washed twice with absolute ethanol. After drying the pellet was resuspended in 360 L of buffer ATL (QIAmp DNA Mini Kit, Qiagen, Germany) and incubated at 95ºC for 15 minutes and then cooled to room temperature. Samples were then digested with proteinase K for 3 days at 56ºC in a rotation oven with periodic mixing and the addition of fresh proteinase K every 24 hours.
DNA was collected using the QIAmp DNA Mini Kit according to the manufacturer's instructions. Briefly, 400 L of buffer AL was added to the sample and incubated at 70ºC for 10 minutes. 400 L of absolute ethanol was then added. The sample solution was then placed into the spin column and centrifuged for 1 minute at 8000 x g. The spin column was washed twice with 500 L of AW1 by centrifugation at 8000 x g for one minute and then washed with AW2 by centrifugation at 14,000 x g for three minutes.
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The DNA was finally eluted with 55 L buffer AE. Extracted DNA was quantified on a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). All samples used in this study had an OD 260/280 ratio higher than 1.8.
Extracted DNA from each sample was processed following the manufacturer's protocol and hybridized on Affymetrix GeneChip Genome-Wide Human SNP Array 5.0® (Affymetrix, Santa Clara, CA, USA). Because DNA extracted from FFPE samples was degenerated, the following modifications were adopted to the oligonucleotide microarray system, taking into consideration previous studies (20, 21, 23) : the initial DNA amount was increased from 250 ng to 1 g; digestion time was prolonged from 120 minutes to overnight; the volume of PCR reactions was increased when the yields of PCR product failed to reach prescribed levels. The peak size of mapping PCR products was determined by visual inspection of electropherograms following 2% TBE agarose gel electrophoresis.
SNP array data analyses
All signal intensities of probes and genotype calls were generated and obtained from Genotyping Console 3.0.1 ® (BRLMM-P algorithm) using default parameter settings.
Overall hybridization quality was estimated by a generated QC call rate index. We use the term "copy number change" meaning deletion or amplification of a genomic region and "CNLOH" meaning copy number neutral loss of heterozygosity.
Copy number change and LOH analyses (called here SNPaCGH) were conducted using the Partek Genomics Suite (PGS) version 6.3 (Partek, St. Louis, MI, USA). When signal intensities of probes were imported from CEL files into PGS, a normalization procedure with correction for GC-content and fragment length effects was performed.
Copy number estimates from signal intensities were determined by "paired analysis", to compare copy number state from tumor and matching normal tissue. Detection of amplifications and deletions was performed with a segmentation algorithm in the copy number workflow in PGS, where the minimum marker size was set at 150 (default setting is 10) and signal/noise ratio was set at 0.25 (default setting is 0.30). Genotype calls data were imported from CHP files into PGS following the restriction of SNPs to fragment sizes ≤500 bp, because genotype calls of SNPs on longer fragments are 7 unreliable from degenerated DNA, such as DNA extracted from FFPE samples (20) . LOH values were inferred by paired analysis with the Hidden Markov Model default setting in the LOH Workflow in PGS. All of these modifications from the default settings are adopted to maximize detection specificity.
Quantitative PCR (qPCR) assay
Quantitative PCR analyses to validate copy number changes were performed on a LightCycler® 480 Real-Time PCR System (Roche Diagnostics, Mannheim, Germany) using an intercalating dye, SYTO13 (Molecular probes, OR, USA), which is an alternative to SYBR green I. Absolute quantification was carried out using a second derivative max method (24) . A standard calibration curve was generated with a serial dilution of genomic DNA to estimate the copy number state of sample for each set of BLAST searches confirmed all primer sequences to be specific for the gene. The data were analyzed using LightCycler® 480 Basic Software (Roche Diagnostics) and melting curve analysis was always performed to verify the absence of non-specific amplification.
Statistical analysis
To estimate the total rate of a copy number changed region, each segment amplified or lost was summed and divided by 2,829 Mb, which is the total Mb in the genome, excluding heterochromatic, centromeric and telomeric regions not covered by probes.
Similarly, to estimate the total rate of genomic alteration, the sum of segments with copy number change and CNLOH was divided by 2,829 Mb. Wilcoxon's rank sum test and Kruskal-Wallis' chi-squared test were performed to compare the rate of copy number change and genomic alteration between subgroups.
To determine successful predictive factors for the analysis of FFPE samples, Pearson's product-moment coefficient of correlation test was performed with the QC call rate.
The analyses above were done with the free statistical program, R (version 2.8.0) (http://www.r-project.org/) and the results were considered statistically significant when the p-value was <0.05. To determine what kinds of genes were contained in the gene lists, Gene Set Enrichment Analysis (GSEA) was performed with the H-InvDB Enrichment Analysis Tool (HEAT) (25) . These results were considered statistically significant when the p-value for Fisher's exact probability test was <0.001.
RESULTS
Performance of array hybridization
The QC call rates obtained from the FFPE samples were from 70.75 to 91.93 %, with a mean of 80.72 % ( Table 1, Supplementary Table 1) . A highly significant liner correlation between the peak size of the mapping PCR product and the QC call rate was observed (r = 0.85, P ≤ 0.0001). Also significant negative liner correlation between the duration of storage and the QC call rate was observed (r = -0.70, P < 0.006) (Supplementary figure 1) . Yields of genomic DNA and PCR product showed no significant correlations with QC call rate (data not shown).
Genomic alterations detected by GeneChip Genome-Wide Human SNP 6.0 arrays and correlations with clinical characteristics
In genome-wide copy number and LOH analysis, substantial divergence was observed between each ICPT subtype ( Figure 2) . The mean rate of copy number change was 0.48% (from 0.0% to 1.60%), 7.89% (from 0.41% to 12.0%) and 16.3% (from 16.0% to 16.6%) in Pap, PC and PCinv, respectively. The mean rate of genomic alteration (including copy number change and CNLOH) was 2.87% (from 0.00% to 11.8%), 15.4% (from 8.83% to 24.1%) and 35.3% (from 17.6% to 53.1%) in Pap, PC and PCinv, respectively (Table 1) . Malignant tumors (PurePC and PCinv) showed significantly more copy number changes and genomic alterations (copy number change and CNLOH) than benign tumors (Pap) (Wilcoxon's rank sum test, p = 0.036, 0.016 respectively) ( Figure 3 ) and these differences correlated with their malignant phenotype (Kruskal-Wallis' chi-squared test, p = 0.046, 0.043, respectively) (Fig 4) .
Copy number validation by qPCR assay
To validate the copy number change identified by SNPaCGH, quantitative PCR assays were performed at four selected loci, including independent genes ( Table 2 ). All loci showing alteration were confirmed by real-time qPCR. This indicated that the detection specificity of copy number change in SNPaCGH was 100%. On the other hand, at 31 loci from the ten samples, where SNPaCGH showed the copy number state as disomy, ten loci were revealed to have a copy number change by real-time qPCR. At regions determined to be disomy by SNPaCGH, 70.6 % were determined by qPCR to be 10 two copy. The copy number calling concordant rate between benign (Pap) and malignant (PurePC + PCinv) tumors was not significant (Fisher's exact test, p = 0.31), at 73.7% and 58.3% respectively.
Genes within frequently altered chromosomal regions
Among five carcinomas we identified 3 or more that had 93 regions of chromosomal alteration (Supplementary table 2 (Table 4) .
DISCUSSION
In breast lesions, indication for surgery is usually determined by pathological diagnosis together with radiological findings but differential, preoperative diagnosis of papillary carcinoma from papilloma is very difficult, even following needle biopsy (26) because of their non-specific radiological characteristics and their modest cytological and histological appearance (6) . Hence, in the clinical management of these lesions, surgical excision is recommended, especially when associated to identified risk factors of malignancy, such as high age (≥ 50 years) and the presence of microcalcifications (27, 28) . In the cases presented in this study, we also needed to conduct surgery since we couldn't determine lesion malignancy ( Figure 1 , Table 1 ). To avoid excessive surgical intervention, another diagnostic procedure needs to be developed.
In the present study, we have compared the molecular profiles of papilloma versus papillary carcinoma through a genome-wide copy number and LOH analysis using new technology: high-density oligonucleotide SNP microarrays. Although several studies have compared the molecular profiles of papilloma versus papillary carcinoma (2, 7-10), the differences between these profiles were not conclusive. Some studies indicated that papillary carcinoma harbored more genomic alterations than papilloma (7-9) but other studies indicated that papilloma also had substantial genomic alterations (2, 10).
Our SNPaCGH results indicated that papillary carcinoma harbored significantly more genomic alterations than papilloma, even though papilloma had a number of genomic alterations, and that the rate of genomic alteration correlated with pathological malignancy classification. Our findings also suggest that SNPaCGH could be a new preoperative diagnostic method for papillary lesions. We need to analyze more samples to confirm our findings. Also a prospective study using high-density SNP arrays and specimens from preoperative core-needle biopsies is required for practical clinical application.
Previous studies have documented that the most common genomic alteration in papillary carcinoma is amplification on 1p and deletion or LOH on 16q (2, 7, 8, 10).
Our study revealed deletion or CNLOH on 3p and amplification on 20q in addition to deletion or CNLOH on 16q (Figure 2 , Table 3, Supplementary table 2) . Intriguingly, this profile is similar to intraductal or invasive ductal carcinoma(9) and these regions contain SNAI1 previously linked to breast cancer biology (29) . The significance of 3p and 20q are currently unclear but require further investigation.
Some interesting genes are included in the "invasion gene list". MAML1 (30) , located at 5q35, is a transcriptional coactivator for NOTCH proteins, E2F1 (31), located at 20q11.22, is a transcriptional activator that cooperatively binds DNA with dp proteins through the E2 recognition site and TPT1 (32) , located at 13q14.12, is involved in calcium binding and microtubule stabilization. These genes have been previously reported to be involved in cancer. Thus, this list identifies genes for further mechanistic research and could include several future therapeutic targets.
In this study, we applied degraded DNA, extracted from FFPE samples, to highdensity SNP arrays. When degraded DNA is used with the Affymetrix GeneChip system the intensities of probe signals hybridized to long fragments tend to be weakened, which would cause artificial copy number change. To resolve this problem, previous studies modified the extraction protocol and/or filtered out signals expected to result from hybridization of long DNA fragments (20) (21) (22) (23) 33) . Referring to these studies, we have adopted the modifications described above. The QC call rate obtained in this study ranged from 70.75 to 91.93%, with a mean of 80.72%, which was comparable to the results from former cytogenetic studies using DNA extracted from FFPE samples. For "paired analysis", QC call rate would not be important for copy number state estimation and LOH detection. QC call rate itself is calculated from the call of SNPs that are relatively difficult to genotype, even using high quality DNA.
Because concordance between tumor and non-tumor SNP call is important to detect LOH with or without deletion, a critical factor using FFPE samples is to use tumor and non-tumor tissues from the same slice samples. "Paired analyses" from the same FFPE sample will assure the concordance of SNP calls and hybridization intensities.
Moreover, validation of the copy number state in SNPaCGH by real time qPCR has demonstrated good specificity. The relatively low concordant copy number state between SNPaCGH and qPCR in disomy regions could be caused by the copy number detection setting, which was adopted to minimize false positive detection and maximize detection specificity. For example, a tiny region with copy number change that is detected by real time qPCR would be overlooked by SNPaCGH analysis using this setting. Even if this experimental error is taken into consideration, our results of 13 significant genomic alteration difference between papilloma and papillary carcinoma is still acceptable because the sensitivity in papilloma and in papillary carcinoma is not significantly different. Thus FFPE samples, which are accessible and associated with much clinicopathological information, will be useful, especially for cytogenetic analyses of rare phenotypes. In addition, the methodology described here can be adapted to other kinds of carcinoma.
In summary, we have elucidated significant differences in the molecular-cytogenetic profile between papilloma and papillary carcinoma from FFPE samples by genomewide copy number and LOH analysis using high-density single-nucleotide polymorphism microarrays. Our data encourage us to exploit a vast number of archived FFPE samples to investigate the biology of a variety of cancers, including breast cancer.
The genes contained in common altered regions are fascinating candidates for further research to unravel the mechanisms of tumorigenesis and invasion of breast cancer.
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